These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 13802238)

  • 21. The bronchoconstrictor action of bradykinin in the guinea-pig.
    COLLIER HO; HOLGATE JA; SCHACHTER M; SHORLEY PG
    Br J Pharmacol Chemother; 1960 Jun; 15(2):290-7. PubMed ID: 13811230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analgesic-antipyretic drugs as inhibitors of kallikrein.
    NORTHOVER BJ; SUBRAMANIAN G
    Br J Pharmacol Chemother; 1961 Aug; 17(1):107-15. PubMed ID: 13729628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological activity of synthetic polypeptides with bradykinin-like properties.
    KONZETT H; STURMER E
    Br J Pharmacol Chemother; 1960 Dec; 15(4):544-51. PubMed ID: 13753032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides.
    Campbell DJ
    Braz J Med Biol Res; 2000 Jun; 33(6):665-77. PubMed ID: 10829095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Kallikrein-kinin system and active peptides in the blood].
    Suzuki T; Nagasawa S
    Tanpakushitsu Kakusan Koso; 1967 Mar; 12(3):201-10. PubMed ID: 4864449
    [No Abstract]   [Full Text] [Related]  

  • 26. A spectrum of pharmacological activity in some biologically active peptides.
    BISSET GW; LEWIS GP
    Br J Pharmacol Chemother; 1962 Aug; 19(1):168-82. PubMed ID: 13869527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of kinin, kallidin, and bradykinin.
    HOLDSTOCK DJ; MATHIAS AP; SCHACHTER M
    Br J Pharmacol Chemother; 1957 Jun; 12(2):149-58. PubMed ID: 13446366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen.
    Lima AR; Alves FM; Angelo PF; Andrade D; Blaber SI; Blaber M; Juliano L; Juliano MA
    Biol Chem; 2008 Dec; 389(12):1487-94. PubMed ID: 18844446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bradykinin and Kallidin].
    HOLTZ P; HEICKE B; BARCK S
    Experientia; 1962 Apr; 18():184-5. PubMed ID: 13908606
    [No Abstract]   [Full Text] [Related]  

  • 30. Action of horse urinary kallikrein on synthetic derivatives of bradykinin.
    Babel I; Stella RC; Prado ES
    Biochem Pharmacol; 1968 Oct; 17(10):2232-4. PubMed ID: 5748672
    [No Abstract]   [Full Text] [Related]  

  • 31. Hydrolysis of rat high molecular weight kininogen by purified rat urinary kallikrein: identification of bradykinin as the kinin formed.
    Girolami JP; Alhenc-Gelas F; Dos Reis ML; Bascands JL; Suc JM; Corvol P; Menard J
    Adv Exp Med Biol; 1986; 198 Pt A():137-45. PubMed ID: 3643701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertensive effects of bradykinin and anephrotensin in normal and nephrectomized animals.
    CROXATTO H; BELMAR J; PEREDA T; LABARCA E
    Acta Physiol Lat Am; 1962; 12():19-21. PubMed ID: 13882445
    [No Abstract]   [Full Text] [Related]  

  • 33. Release of [hydroxyproline3]-kinins by tissue kallikreins of pig, rat and man.
    Maier M; Reissert G; Jerabek I; Bergmann I; Balaun E; Lottspeich F; Binder BR
    Biochem Pharmacol; 1990 Feb; 39(3):549-53. PubMed ID: 2306266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A STABLE SUBSTRATE FOR THE ASSAY OF PLASMA KININ-FORMING ENZYMES.
    AMUNDSEN E; NUSTAD K; WAALER B
    Br J Pharmacol Chemother; 1963 Dec; 21(3):500-8. PubMed ID: 14110750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonistic effect of kallikrein against bradykinin.
    Ercan ZS; Türker RK; Torunoglu M
    Arzneimittelforschung; 1978; 28(10):1712-4. PubMed ID: 582675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational and biological properties of Bauhinia bauhinioides kallikrein inhibitor fragments with bradykinin-like activities.
    Alves FL; Oliva ML; Miranda A
    J Pept Sci; 2015 Jun; 21(6):495-500. PubMed ID: 25902925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further characterization of monoclonal antibodies against rat plasma kallikrein, rat low molecular weight kininogen and synthetic bradykinin.
    Bedi GS; Back N
    Adv Exp Med Biol; 1989; 247B():223-30. PubMed ID: 2610064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biochemical remarks on therapy with kallikrein and kallikrein inactivator].
    WERLE E
    Langenbecks Arch Klin Chir Ver Dtsch Z Chir; 1963; 303():5-10. PubMed ID: 14000005
    [No Abstract]   [Full Text] [Related]  

  • 39. [Bradykinin. Structure--synthesis--physio-pharmacological basis].
    KONZETT H; STURMER E; CERLETTI A
    Clin Ter; 1961 Jan; 20():21-34. PubMed ID: 13753031
    [No Abstract]   [Full Text] [Related]  

  • 40. ENDOGENEOUS MECHANISMS IN INCREASED VASCULAR PERMEABILITY IN INFLAMMATION.
    HAYASHI H
    Acta Pathol Jpn; 1963 Oct; 13():213-5. PubMed ID: 14195178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.